M.E. Thase, R. Entsuah, R.L. Rudolph - Vol. 8, September 2002, Issue 3
Testo Immagini Bibliografia Summary Indice
Tassi di remissione durante trattamento con venlafaxina
o con gli inibitori selettivi del reuptake della serotonina
Remission rates during treatment with venlafaxine
or selective serotonin reuptake inhibitors
2 Depression Guideline Panel. Depression in Primary Care. Volume 2. Treatment of Major Depression. Clinical Practice Guideline No. 5, AHCPR Publication No. 93-0551. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.
3 Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5.
4 Thase ME, Simons AD, McGeary J, Cahalane JF, Hughes C, Harden T, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry, 1992;149:1046-52.
5 Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996;153:945-7.
6 Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, et al. The treatment of chronic depression. Part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-19.
7 Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
8 Clerc GE, Ruimy P, Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
9 Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
10 Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-8.
11 Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-81.
12 Salinas E, for the Venlafaxine XR 367 Study Group. Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 1997;42 (Suppl.1):244S.
13 Rudolph RL, Entsuah R, Aguiar L, et al. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Eur Neuropsychopharmacol 1998;8 (Suppl.2):S142.
14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA, 1987.
15 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA, 1994.
16 Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960;23:56-62.
17 Montgomery SA, åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
18 National Institute of Mental Health. Clinical Global Impressions. Psychopharmacol Bull 1985;21:839-43.
19 Rothman KJ. Modern Epidemiology. Boston, MA: Little, Brown & Co, 1986.
20 Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume I. The Analysis of Case-Control Studies. Lyons: IARC Scientific Publications, 1980.
21 Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA, Hurley K, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-15.
22 American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(Suppl.4):1-26.
23 Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 1999;60(Suppl.4):23-32.
24 Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163(Suppl.21):30-4.
25 Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol (Oxford) 1994;8:238-49.
26 Edwards, JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999:54:507-33.
27 Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991;303:685-92.
28 Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
29 DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. Medication versus cognitive behavior therapy for severely depressed outpatients: meta-analysis of four randomized comparisons. Am J Psychiatry 1999;156:1007-13.